ArticleInternational journal of cardiology. Congenital heart disease2026
Changes in pharmacotherapy in adults with Fontan circulation and associations with outcomes.
Article in International journal of cardiology. Congenital heart disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are limited data on pharmacologic management of adults living with Fontan circulation. Objectives: We planned to define changes in pharmacologic management of adults living with Fontan circulation seen at our adult congenital heart disease (ACHD) center and evaluate the association between medication changes and outcomes. Methods: We conducted a single center retrospective study. Patient characteristics, cardiac medications, and medication start dates were abstracted by electronic medical record review. Outcomes investigated were new-onset arrhythmia, first time heart failure hospitalization, and transplant-free survival. Outcomes were compared between patients who started medications while under ACHD care with those who did not. Results: The most common cardiac medication class prescribed to patients prior to establishing care was angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) (51.0%), followed by loop diuretics (28.2%) and mineralocorticoid receptor antagonists (MRA) (18.6%). There was a higher incidence of first time heart failure hospitalization and heart transplant or death in patients started on nearly all cardiac medication classes compared to those who were not. Patients started on anti-arrhythmics, loop diuretics, MRA, pulmonary vasodilators, and warfarin had the lowest 5-year transplant-free survival from medication start date. Conclusions: We report commonly utilized cardiac medication classes in adults living with Fontan circulation, with our data suggesting that patients starting anti-arrhythmics, loop diuretics, MRA, pulmonary vasodilators, and warfarin may have decreased 5-year transplant-free survival from medication initiation. These medications were often started in patients with Fontan circulatory failure and/or cirrhosis, suggesting these patients constitute a sicker subset of adults living with Fontan circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.